Compare iShares Gold Trust (IAU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Repligen Corporation Common Stock — how do they compare? iShares Gold Trust trades at $77.66 (market cap $62.13B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: iShares Gold Trust is far larger — about 5.6× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 51 Days and Repligen Corporation Common Stock for 0 Days on average.
| IAU | RGEN | |
|---|---|---|
Market Cap | $62.13B | $11.14B |
Volume | 3,713,095 | 1,259,263 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $194.57 |
52-Week Low | $74.21 | $102.87 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU shares are trading at $78.25, down 0.11% with bearish technical signals dominating the short-term outlook. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has provided some support. Technical indicators show selling pressure outweighing buying signals, with moving averages pointing downward and key resistance at $79.
The stock faces headwinds from monetary policy uncertainty and yield pressures, but potential exists if inflation concerns resurface. Key risks include continued rate hike expectations and dollar strength, while opportunities may emerge from safe-haven demand during market volatility. The technical setup suggests caution in the near term with support at $78.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
